TSC2 and lymphangioleiomyomatosis: Compared with patients registered in TOSCA, our cohort being evaluated for LAM tended to have been diagnosed with TSC at an older age, had a lower prevalence of neurological and cognitive manifestations, were more likely to have angiomyolipoma and more likely to have TSC2 mutations than TSC1 or no identifiable mutation (Fig. 2).